Integration af nye og fremtidige biologiske markörer i behandling af cancer mammae
Sammanfattning
In the management of breast cancer patients, there is a need for the development of new and efficient biomarkers to be used for early detection/screening, prognostic evaluation, prediction of therapy sensitivity/resistance and disease monitoring. It is emphasized that before a new biomarker can be implemented in the routine treatment of breast cancer patients, its value must be proven in high-powered, prospective clinical trials. This paper describes each of the above-mentioned indications followed by information on the present status for their development in breast cancer.